Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study-Reference-Cited by-同舟云学术

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study

Published:2017-12 Issue:8 Volume:17 Page:601-610.e2
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Lambertini Matteo^ORCID,Ferreira Arlindo R.,Di Meglio Antonio^ORCID,Poggio Francesca,Puglisi Fabio^ORCID,Sottotetti Federico,Montemurro Filippo,Poletto Elena,Bernardo Antonio,Risi Emanuela^ORCID,Dellepiane Chiara^ORCID,Sini Valentina,Minuti Gabriele,Grasso Donatella,Fancelli Sara,Del Mastro Lucia

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol,2014

2. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Breast,2014

3. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study;Ellis;J Clin Oncol,2015

4. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015

5. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States;Iqbal;JAMA,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry;Breast Cancer Research and Treatment;2024-02-21

2. Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry;2023-10-03

3. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer;npj Breast Cancer;2023-06-02

4. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference—a Dutch population-based study from 2008 to 2018;Breast Cancer Research and Treatment;2023-01-17

5. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference - a Dutch population based study from 2008-2018.;2022-08-08